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Background: Despite the global distribution of 
the intestinal protozoan  Dientamoeba fragilis,  its 
clinical picture remains unclear. This results from 
underdiagnosis: microscopic screening methods 
either lack sensitivity (wet preparation) or fail to 
reveal  Dientamoeba  (formalin-fixed sample). Aim: In 
a retrospective study setting, we characterised the 
clinical picture of dientamoebiasis and compared it 
with giardiasis. In addition, we evaluated an improved 
approach to formalin-fixed samples for suitability 
in  Dientamoeba diagnostics. Methods: This study 
comprised four parts: (i) a descriptive part scrutinising 
rates of  Dientamoeba  findings; (ii) a methodological 
part analysing an approach to detect  Dientamoeba-
like structures in formalin samples; (iii) a clinical part 
comparing demographics and symptoms between 
patients with dientamoebiasis (n = 352) and giar-
diasis (n = 272), and (iv) a therapeutic part (n = 89 
patients) investigating correlation between faecal 
eradication and clinical improvement. Results: The 
rate of  Dientamoeba  findings increased 20-fold after 
introducing criteria for Dientamoeba-like structures in 
formalin-fixed samples (88.9% sensitivity and 83.3% 
specificity). A further increase was seen after imple-
menting faecal PCR. Compared with patients with 
giardiasis, the symptoms in the  Dientamoeba  group 
lasted longer and more often included abdominal 
pain, cramping, faecal urgency and loose rather than 
watery stools. Resolved symptoms correlated with 
successful faecal eradication (p < 0.001). Conclusions: 
Previously underdiagnosed, Dientamoeba has become 
the most frequently recorded pathogenic entero-
parasite in Finland. This presumably results from 
improved diagnostics with either PCR or detection 
of Dientamoeba-like structures in formalin-fixed sam-
ples, an approach applicable also in resource-poor 
settings. Symptoms of dientamoebiasis differ slightly 
from those of giardiasis; patients with distressing 
symptoms require treatment.
Introduction
Despite the worldwide distribution of the enteropara-
site  Dientamoeba fragilis, its prevalence and clinical 
significance have remained obscure [1,2]. Spread by 
the faecal-oral route appears most likely [2]. Recently, 
a cyst stage was discovered [3,4] and its transmission 
– and association of the protozoan with symptomatic 
disease – was shown in a rat model [3,4]. Acquisition 
together with pinworms has also been suggested [1].
Historically,  Dientamoeba  has often remained 
undetected because of shortcomings of the stool 
parasite screening methods generally used: formalin-
fixed samples were not considered applicable to 
detecting  Dientamoeba  and wet preparation has poor 
sensitivity [5]. Instead, diagnosis has required micros-
copy of specifically stained fresh stool samples (tri-
chrome or modified iron-haematoxylin staining) [6-9] 
and clinicians familiar with the protozoan knowing how 
to search for it. Today, PCR methods have become avail-
able in many laboratories. The advantages of these 
methods are obvious, but results from studies using 
them vary considerably: prevalences between 0.2% 
and 71% have been reported [2], and some commer-
cial assays have been shown to misidentify the animal 
protozoan  Tritrichomonas foetus  as  Dientamoeba  [10]. 
Nevertheless, now that the PCR methods have been 
widely adopted in the more affluent parts of the world, 
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the reported prevalence of Dientamoeba is higher than 
when the traditional microscopical methods were used 
[2]. The main reasons for debating the pathogenicity 
of Dientamoeba are its high prevalence in some studies 
[2] and the large proportion of asymptomatic carriage 
ranging from 11% [11] to 39% [12].
The most frequently recorded symptoms include 
abdominal pain and diarrhoea or loose stools [13]; a 
chronic course lasting up to several years has been 
reported for 2% [14] to 32% [15] of the patients. Many 
studies have shown an association between clinical 
improvement and faecal eradication [2,11,16-19], while 
the results for children have been conflicting [20-22]. 
Greater virulence of specific  Dientamoeba  strains has 
been suggested to account for symptomatic disease. 
However, recent investigations suggest that there are 
only two major clonal lines of Dientamoeba worldwide, 
one much more common than the other, which rather 
points to host characteristics bringing about variation 
in the clinical picture [23].
In Finland, clinical experience of dientamoebiasis 
has been accrued since 2007, when our laboratory 
commenced informing clinicians of  Dientamoeba-like 
structures detected in formalin samples, urging 
them to send in additional trichrome-stained sam-
ples. This led to an increase in the number of new 
findings. Later, in 2017, a multiplex PCR method for 
protozoan parasites (Dientamoeba fragilis,  Giardia 
lamblia,  Cryptosporidium parvum,  Entamoeba histol-
ytica) was implemented in clinical practice (Amplidiag 
Stool Parasites test, Mobidiag Ltd, Espoo, Finland) 
[24]. Spurred by the rise in  Dientamoeba  findings, 
we conducted a study depicting this development, 
presenting the formalin sample approach, analyses of 
demographics and clinical picture, and microbiological 
and clinical cure rates after antimicrobial therapy.
Methods
Study outline
We conducted a retrospective study of the diagnostics 
and clinical picture of dientamoebiasis. To this end, we 
collected data on microbiological results and clinical 
symptoms of patients with a positive finding in clinical 
faecal samples examined for Dientamoeba or Giardia in 
the period from January 2007 to March 2012 at Helsinki 
University Hospital Laboratory (HUSLAB).
The investigation comprised four parts: (i) a descriptive 
part relating the annual numbers of new Dientamoeba 
findings from 2007 to 2017; (ii) a methodological part 
presenting an approach to identify  Dientamoeba  in 
formalin-fixed samples and comparing the results to 
those from the same patients’ trichrome samples; (iii) 
a clinical part comparing the demographics and clinical 
picture between patients with dientamoebiasis and 
those with giardiasis; (iv) a therapeutic part analysing 
faecal eradication and clinical outcome after antipara-
sitic treatment.
The HUSLAB database was retrospectively searched 
for  Dientamoeba  and  Giardia  entries dated between 
January 2007 and March 2012.
The diagnosis of dientamoebiasis was based on posi-
tive faecal sample in microscopy after fixation with 
Ecofix (Meridian Bioscience, Inc., Cincinnati, United 
States) and modified trichrome staining [25]. In 2017, 
a multiplex PCR for intestinal protozoa was adopted in 
routine use and therefore, in the descriptive part of the 
study, also positive findings by PCR were covered.
Diagnosis of giardiasis was verified by microscopy of 
formalin-fixed faecal sample, by microscopy of Ecofix-
fixed and trichrome-stained faecal sample or by posi-
tive antigen test (ProSpecT Giardia/Cryptosporidium 
Microplate Assay, Oxoid Ltd, Basingstoke, United 
Kingdom).
Patients with a sample positive for  Dientamoeba  in 
trichrome staining were included in 
the Dientamoeba group and those with a positive sample 
in  Giardia  diagnostics comprised the  Giardia  group. 
To obtain a roughly equal number of patients in both 
groups, initially only the first five positive results 
per month were selected for the  Giardia  group. 
Later, in 2009, when  Dientamoeba  findings 
exceeded  Giardia  findings, all positive results were 
recorded in both groups.
Ethical statement
According to the Finnish Medical Research Act, review 
by an ethics committee is only required for research 
involving intervention. The study protocol was approved 
by the research boards of the Inflammation Center and 
the regional laboratory of HUSLAB, Helsinki University 
Hospital (HUH), and the Department of Social Services 
and Health Care, City of Helsinki.
Methodological part of the study
Formalin-fixed samples were prepared as follows: fae-
cal samples (2–3 g) were fixed with 10 mL of 10% for-
malin, filtered through a cheese cloth to remove large 
debris and concentrated by the standard formalin-
ethyl acetate method [26]. Approximately 25 μL of pel-
let was stained with an equal amount of Lugol’s iodine 
and examined using bright field microscopy by skilled 
laboratory personnel at 100× and 400× magnification 
for 3–5 minutes. In one positive sample, we generally 
identified several Dientamoeba-like structures.
The criteria for  Dientamoeba-like structures in for-
malin-fixed samples were as follows: shape slightly 
flexible, structure round or oval, diameter 8–15 µm; 
surrounded by a thin cell membrane with no resem-
blance to  Entamoeba cysts; coarseness of cytoplasm 
fine to medium; nuclei (if visible), when stained by 
iodine, dot-like. The structures looked jumbled because 
of vacuoles and multiple granules in the cytoplasm.
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For photography, Lugol’s iodine solution was added 
(1:1) and mobility of sample was reduced by adding 
an equal amount of the fluid and acrylamide solution 
before polymerisation (40% acrylamide containing 
0.5% ammonium persulfate and 0.25% TEMED). The 
samples were photographed using a 40× objective in 
a LEICA DM6000 microscope equipped with a LEICA 
DM2900 camera.
To determine the sensitivity and specificity of detect-
ing  Dientamoeba  in formalin-fixed specimens,  the 
results from them were compared with the same 
patients’ trichrome-stained samples. The samples of 
both kinds had either been taken at the same time 
or the trichrome sample shortly afterwards, on the 
laboratory’s recommendation prompted by findings in 
the formalin-fixed sample. For the sake of objectivity, 
we only included in the analyses formalin-fixed 
samples investigated at least 1 day earlier than the 
same patient’s trichrome samples (gold standard).
Clinical part of the study
Clinical data
Demographic data, results of faecal microbiologi-
cal tests and clinical data were retrieved from the 
electronic patient charts of HUH and Helsinki City 
healthcare units. The demographic information com-
prised sex, age and chronic diseases. Symptoms 
were recorded as reported in patient charts by the 
clinicians. Data on treatment were collected only for 
the Dientamoeba group.
Additional microbiological data, when available, 
were collected on faecal pathogens (cultures for   
Salmonella  spp.,  Yersinia  spp.,  Campylobacter  spp. 
and Shigella spp.; culture and toxin test for Clostridium 
difficile; enteric worms and ova (formalin-fixed sam-
ples);  Cryptosporidium  spp. (formalin-fixed modified 
Ziehl-Neelsen staining or antigen test ProSpecT 
Giardia/Cryptosporidium Microplate Assay, Oxoid Ltd, 
Basingstoke, United Kingdom);  Entamoeba histolyt-
ica  (Entamoeba Celisa Path Test Kit, CeLLabs Pty Ltd, 
Sydney, Australia); Enterobius vermicularis (microscopy 
of a perianal cotton swab)). Findings of apathogenic 
faecal microbes, including  Blastocystis hominis,  were 
recorded separately. Samples screened because of 
indications other than gastrointestinal symptoms were 
recorded separately.
Patients with findings positive for other pathogens 
were excluded. Lack of diagnostic samples for other 
pathogens did not lead to exclusion since, as opposed 
to Dientamoeba  [13], bacterial and viral pathogens are 
not common as causes of prolonged intestinal com-
plaints [27,28]. The number of patients with missing 
samples was recorded.
Treatment
Our analysis covered the first course of medication, and 
only patients with at least two control samples taken 
2 weeks or more after completing the course were 
selected. Only data from patients treated with doxy-
cycline, metronidazole, paromomycin or secnidazole 
– the alternatives recommended in the Finnish guide-
lines concerning treatment of dientamoebiasis – were 
included. Data on dosage and regimen duration were 
recorded when available, yet absence of such data did 
not result in exclusion because the recommended regi-
men is uniform in the Finnish guidelines.
Microbiological and clinical outcomes were recorded 
separately. Faecal clearance was evaluated by findings 
in trichrome-stained samples. Two or more negative 
control samples were classified as microbiological suc-
cess, but even one positive control sample sufficed for 
interpretation as microbiological failure. Clinical out-
come was judged by symptoms recorded in the patient 
charts before and after antiparasitic treatment. Clinical 
success was defined as complete or partial relief of 
symptoms. In our clinical experience, as for giardiasis 
[29], it is not uncommon for dientamoebiasis symptoms 
Figure 1
Annual numbers of new Dientamoeba and Giardia 
findings and number of faecal samples investigated at 
HUSLAB, Helsinki, Finland 2007–2017 (n = 189,723 
samples)
0
100
200
300
400
500
600
0
500
1,000
1,500
2,000
2,500
3,000
3,500
4,000
A. Dientamoeba
B. Giardia
2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017a
Findings (n)
Fa
ec
al
 s
am
pl
es
 (n
)
New Dientamoeba findings from PCR samples
New Dientamoeba findings from trichrome samples
Faecal samples (trichrome and PCR)
0
100
200
300
400
500
600
0
2,000
4,000
6,000
8,000
10,000
12,000
14,000
16,000
18,000
20,000
2007 2008b 2009 2010 2011 2012 2013 2014 2015 20162017c
Findings (n)
Fa
ec
al
 s
am
pl
es
 (n
)
New Giardia findings from PCR samples
New Giardia findings from formalin-fixed samples
Faecal samples (formalin-fixed sample and PCR)
HUSLAB: Helsinki University Hospital laboratory.
a All specimens from 2007–16 were trichrome samples. In 2017, 
there were a total of 3,065 faecal specimens, consisting of 1,187 
PCR and 1,878 trichrome samples.
b The peak in new Giardia findings in 2008 was due to a sewage 
epidemic in the town of Nokia, Finland [40].
c All specimens from 2007–16 were formalin samples. In 2017, 
there were a total of 16,422 faecal specimens, comprising 15,235 
formalin and 1,187 PCR samples.
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to be partly relieved, with full clinical recovery only 
occurring weeks after a successful faecal eradication.
Exclusion criteria
Patients were excluded from the methodological analy-
sis if they had not provided either faecal sample, for-
malin-fixed or trichrome-stained, or if their trichrome 
samples had been investigated before their formalin 
samples. As for the clinical part, patients were excluded 
because of (i) a verified positive finding of some other 
intestinal pathogen(s), (ii) missing patient history, (iii) 
a previously diagnosed active chronic gastrointestinal 
disease (e.g. colitis ulcerosa) with or without exacerba-
tion or (iv) samples taken as part of routine screening 
(e.g. recent immigrants). Patients were excluded from 
post-treatment analysis (i) if they had submitted less 
than two control samples or the specimens had been 
taken too early (during the first 2 weeks after complet-
ing the treatment), (ii) if they had received some drug 
other than doxycycline, metronidazole, paromomycin 
or secnidazole, (iii) if they had been asymptomatic 
before the treatment, or (iv) if their post-treatment clin-
ical data was missing.
Statistical analysis
For medians, the range and interquartile range (IQR) 
were determined. Means with standard deviations 
and ranges were calculated. For continuous variables, 
appropriate tests were used (independent samples 
t-test or Mann–Whitney U-test). For categorical vari-
able analyses, the chi-square test was applied. IBM 
SPSS Statistics (versions 21 to 24) software was used 
in statistical analyses.
Results 
Rates of Dientamoeba findings
After adopting the formalin-fixed approach into detec-
tion of  Dientamoeba  in 2007, the number of positive 
trichrome samples multiplied. A steady 20-fold 
increase in new  Dientamoeba  findings was seen 
between 2007 and 2017 (Figure 1A), whereas the num-
ber of  Giardia  findings remained constant (Figure 1B). 
Multiplex PCR for  Dientamoeba fragilis,  Giardia lam-
blia, Cryptosporidium parvum and Entamoeba histolyt-
ica was implemented at the beginning of April 2017 and 
a 28% annual increase in new  Dientamoeba  findings 
was seen in 2017.
Subject groups
During the period from January 2007 to March 2012, we 
collected a total of 802  Dientamoeba  and 849  Giardia 
findings from the HUSLAB database (see Methods 
about equal numbers in the patient groups). Detailed 
information of these entries was available for 44% 
(352/802) of the  Dientamoeba  and 32% (272/849) of 
the  Giardia  patients. Other pathogenic microbes were 
observed in 6% (20/352) of the Dientamoeba and 14% 
(39/272) of the  Giardia  entries, and apathogenic par-
asites in 69% (244/352) and 57% (155/272), respec-
tively; a co-infection of  Dientamoeba  and  Giardia was 
recorded for 11 patients (Supplementary Table S1).
After exclusions (Figure 2), the  Dientamoeba  group 
comprised 319 and the  Giardia  group 160 patients. 
Apathogenic parasites were identified in the speci-
mens, respectively, of 61% (196/319) and 49% (78/160) 
of the patients scrutinised, and  Blastocystis homi-
nis proved the most common apathogen in both groups: 
54% (172/319) and 43% (69/160), respectively.  Table 
1  and  Supplementary Table S1  show the number of 
patients from whom the different faecal pathogens had 
been analysed and the proportions of positive findings 
in the microbiological tests among the two final subject 
groups. 
Figure 2
Study design for a retrospective investigation of patients 
with positive stool findings of Dientamoeba and Giardia, 
Helsinki Metropolitan Area, Finland, 2007–2012 (n = 624)
All cases
n = 624
Dientamoeba group
n = 352
Giardia group
n = 272
Exclusion
Dientamoeba n = 33b
Giardia n = 112c
Demography and
clinical picture
Dientamoeba n = 319
Giardia n = 160
Exclusion
n = 230d
Treatment
n = 89
Method analysis
n = 348a
a Patients with both formalin and trichrome samples.
b Exclusion because of: findings of other concomitant pathogens 
(n = 20), initial diagnosis from immigration screening (n = 6), case 
history missing (n = 5) or active gastrointestinal disease (n = 2).
c Exclusion because of: findings of other concomitant pathogens 
(n = 39), initial diagnosis from immigration screening (n = 55), 
case history missing (n = 17) or active gastrointestinal disease 
(n = 1).
d Exclusion because of: no data available on treatment (n = 19), 
less than two faecal control samples collected or control 
samples taken too early (n = 172), antimicrobial drug other than 
doxycycline, metronidazole, paromomycin or secnidazole (n = 5), 
post-treatment clinical data missing (n = 14) or asymptomatic 
before treatment (n = 20).
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The demographics were similar for both groups (Table 
2): 49% (157/319) of the Dientamoeba patients and 54% 
(86/160) of the  Giardia  patients were female; the age 
medians were 29 years (IQR: 8–47; range: 1–82 and 31 
years (IQR: 20–45; range: 1–76), respectively. The two 
groups had similar age distributions. An underlying 
chronic disease was reported for 35% (113/319) 
of the  Dientamoeba  patients and 32% (51/160) of 
the Giardia patients.
Table 1
Number of faecal samples and results of analyses among patients with dientamoebiasis and giardiasis, Helsinki 
Metropolitan Area, Finland, 2007–2012 (n = 479)
Faecal samples
Dientamoeba (n = 319) Giardia (n = 160)
n % of patients n % of patients
Formalin-fixed samplea
Patients with sample 289 91 159 99
Dientamoeba-positive 251 79 0 0
Giardia-positive 0 0 156 98
Trichrome sample
Patients with sample 319 100 20 13
Dientamoeba-positive 319 100 0 0
Giardia-positive 0 0 18 11
Giardia/Cryptosporidium antigen testb
Patients with sample 54 17 37 23
Giardia-positive 0 0 25 16
Cryptosporidium-positive 0 0 0 0
Enterobiasis cotton swab
Patients with sample 32 10 13 8
Enterobiasis-positive 6 2 8 5
Faecal bacterial culture
Patients with sample 166 52 111 69
Sample positive for pathogensc 0 0 0 0
Clostridium samplesd
Patients with sample 68 21 27 17
Clostridium-positive 0 0 0 0
Entamoeba histolytica samplee
Patients with sample 40 13 10 6
E. histolytica-positive 0 0 0 0
a Dientamoeba positivity is indicated by Dientamoeba-like structures observed in microscopy of formalin sample.
b Formalin-fixed modified Ziehl-Nielsen staining or antigen test (ProSpecT Giardia/Cryptosporidium Microplate Assay, Oxoid Ltd, Basingstoke, 
United Kingdom).
c Culture for Salmonella spp., Yersinia spp., Shigella spp. and Campylobacter spp.
d Culture and toxin test.
e Entamoeba histolytica (Entamoeba Celisa Path Test Kit, CeLLabs Pty Ltd, Sydney, Australia).
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Dientamoeba-like structures in formalin-fixed 
samples: specificity and sensitivity
Figure 3  shows nine representative formalin-fixed 
samples with  Dientamoeba-like structures from 8.5 to 
17 μm in diameter, round or oval in shape, and with a 
thin cellular wall. Inside them there were variable num-
bers (two to six) of darker staining areas with a diam-
eter of ca 0.5 to 1.0 μm. These intracellular structures 
had a surrounding halo; their identity has not been 
confirmed, but some of them might be nuclei of the 
organism. For the formalin sample to be interpreted 
as positive for  Dientamoeba-like structures, size and 
inner structures were the main criteria.
 
A total of 363 patients (320 from the Dientamoeba and 
43 from the Giardia group) had provided both formalin-
fixed and trichrome-stained specimens. The trichrome 
sample had been examined before the formalin sample 
for 4% (15/363) of patients; these were excluded 
from further analyses. Judged by results of trichrome 
staining, 77% (268/348) of the formalin-fixed samples 
proved true Dientamoeba positives, 2% false positives 
(7/348), 11% false negatives (38/348), and 10% 
(35/348) true negatives. A sensitivity of 89% (95% 
confidence interval (CI): 85.2–92.1) and specificity of 
83% (95% CI: 68.6–93.3) were recorded for formalin-
fixed specimens in detecting Dientamoeba.
Symptoms
A total of 85% Dientamoeba and 88% Giardia patients 
had reported symptoms, most commonly diarrhoea, 
prolonged diarrhoea (lasting over 2 weeks), abdominal 
pain and flatulence, and abdominal swelling or 
discomfort (Table 3). The indications for stool sample 
screening among asymptomatic patients are given 
in  Table 3.  Dientamoeba  patients differed from those 
with Giardia in reporting more frequently loose stools, 
abdominal pain, constipation and faecal urgency. 
Symptoms had persisted considerably longer in 
the Dientamoeba group before a correct diagnosis had 
been made.
Within the  Dientamoeba  group, abdominal pain and 
cramping had been reported more frequently among 
the patients younger than 18 years than among the 
adults (64% vs 49%, p = 0.006, chi-square test); 
flatulence, abdominal swelling and discomfort had 
Table 2
Demographics of patients with dientamoebiasis and giardiasis, Helsinki Metropolitan Area, Finland, 2007–2012
Characteristics Dientamoeba (n = 319) Giardia (n = 160) p value
Sex (n)
Male 162 74
0.349a 
Female 157 86
Age (years)
Median 29 31 0.266b  
IQR 8–47 20–45
Range 1–81 1–76
Age groups (n)
0–6 64 17
7–15 66 17
16–29 32 41
30–49 85 58
50–69 61 20
≥ 70 11 7
Chronic diseases (n) 113 51 0.476a
IQR: interquartile range.
a Chi-square test.
b Mann–Whitney U-test.
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been more commonly listed by the adults (20% vs 42%, 
p < 0.001, chi-square test).
Clinical success and parasite eradication
Of the 319 patients with  Dientamoeba, 28% (89/319) 
were included in the therapeutic part of the study 
(Figure 2). Data on dosage and regimen are shown 
in Supplementary Table S2. The median time until the 
first control sample was 36 days (IQR: 29–62; range: 
16–298) and until the second, it was 76 days (IQR: 
40–132; range: 16–378) after completing treatment.
Of all  Dientamoeba  patients treated, clinical success 
had been reported by the physician for 66% (59/89) 
and eradication of the parasite from faeces was 
observed for 53% (47/89). Partial resolution of 
symptoms was seen among 25 of 59 patients with 
clinical success. Clinical success was more frequent 
among patients with successful eradication: 39 of 59 vs 
eight of 30, with p < 0.001 (chi-square test). The same 
result was seen in a subgroup analysis of adults (≥ 18 
years: n = 63; p < 0.001, chi-square test), whereas in the 
subgroup of those under 18 years, clinical success did 
not correlate with eradication of parasites from stool 
(n = 26; p = 0.683, Fisher’s exact test). When comparing 
treatment success between the subgroups, faecal 
clearance was more common among adults than those 
under 18 years (59% vs 38%), yet the difference was 
not significant (p = 0.104, chi-square test). Clinical 
success was not found to differ between the two age 
groups (68% vs 62%; p = 0.624, chi-square test).
Discussion
This investigation yielded four noteworthy findings: 
(i)  Dientamoeba  fragilis  can be detected in formalin 
samples with high sensitivity and specificity; (ii) the 
clinical picture of dientamoebiasis differs in several 
aspects from that of giardiasis; (iii) faecal clearance 
of the parasite is associated with alleviation of symp-
toms especially among the adult population; (iv) in 
2017,  Dientamoeba  was the most common pathogenic 
parasitological finding in the Helsinki Metropolitan 
Area.
Formalin fixation approach in diagnostics
While microscopy of wet preparations enables detec-
tion of  Dientamoeba  with very low sensitivity [5], 
formalin-fixed samples have not allowed detection at 
all. In countries like Finland, where classical formalin-
fixed samples have been used as the sole approach 
(until 2017) to screen for stool parasites, the practise 
has inevitably led to underdiagnostics of Dientamoeba. 
This is clearly evidenced by the 20-fold upsurge 
of new  Dientamoeba  findings over the 10-year-
period after adopting in 2007 our novel approach to 
identify  Dientamoeba-like structures in formalin-fixed 
samples. Indeed, the number of Dientamoeba findings 
exceeded Giardia already before the availability of the 
PCR methods in 2017. With a specificity of 83.3% and 
sensitivity of 88.9%, identification of  Dientamoeba-
like structures has proved a viable screening method 
even if – like all other parasitological microscopy – it 
requires a trained technician. Nevertheless, as a major 
advantage over PCR methodology in global settings, 
by identifying Dientamoeba  in formalin-fixed samples, 
diagnostics can also be considerably improved in 
indigent regions where this is the sole approach 
available.
Demographics
Concurring with large epidemiological surveys 
from Denmark [30], the two largest age cohorts in 
the  Dientamoeba group appeared to be daycare and 
school children, and 30- to 49-year-olds. This finding 
accords with the conception of  Dientamoeba  infecting 
especially daycare-aged children and those caring for 
them [31,32]. This was the first investigation to com-
pare chronic illnesses between patients with dienta-
moebiasis and those with giardiasis; no significant 
differences were found.
Symptoms
As in previous studies [13,15], the Dientamoeba group 
was characterised by a prolonged course of disease 
(median 180 days). Low awareness of the disease 
among practitioners and diagnostic difficulties 
presumably accounted at least partly for such late 
diagnosis.
Figure 3
Identification of Dientamoeba fragilis from formalin-fixed 
faecal samples, Helsinki Metropolitan Area, Finland, 
March 2015 (n = 8)
Nine panels showing representative Dientamoeba-like structures 
in formalin samples from eight patients with typical D. fragilis 
trophozoites in trichrome-stained faecal smears. The line 
indicating the scale in each panel corresponds to 10 µm. The 
largest Dientamoeba-like structures in the picture are seen in 
the middle panel of the second row and the left panel of the 
bottom row (13 × 17 and 12 × 17 µm).
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The most common symptoms in the Dientamoeba group 
were loose stools, abdominal pain and flatus or 
abdominal discomfort, all in accordance with earlier 
studies [2,13]. Our data confirmed previously reported 
differences in clinical presentations between dientamoe-
biasis and giardiasis [16]: stomach ache and loose stools 
were more frequent among  Dientamoeba  patients, 
while those with  Giardia  more often reported severe 
illness, watery diarrhoea and even fever. In contrast to 
a previous investigation [9], faecal urgency was more 
frequent in the  Dientamoeba  than the  Giardia  group: 
this may reflect colonic mucosal irritation induced 
by  Dientamoeba  [2], whereas  Giardia  is generally 
known to cause disease in the jejunum.
Table 3
Clinical symptoms of patients with dientamoebiasis and giardiasis, Helsinki Metropolitan Area, Finland, 2007–2012 
(n = 479)
Symptoms
Dientamoeba (n = 319) Giardia (n = 160)
p value
n % n %
Symptomatic 270 85 140 88 NS
Diarrhoea (all) 202 64 116 72 0.034
Watery stools 41 13 54 34 < 0.001
Loose stools 145 46 55 34 0.023
Both watery and loose stools 16 5 7 4 NS
Continuous diarrhoea ≥ 2 weeks 160 50 100 63 0.011
Abdominal pain and cramps 175 55 72 45 0.043
Flatus, abdominal swelling and 
discomfort 104 33 72 45 NS
Nausea 40 13 46 29 < 0.001
Weight loss 37 12 17 11 NS
Vomiting 30 9 19 12 NS
Fatigue 27 9 12 8 NS
Fever 27 9 24 15 0.025
Constipation 23 7 4 3 0.036
Anal pruritus 23 7 6 4 NS
Faecal urgency 14 4 0 0 0.026
Bloody stools 11 3 2 1 NSa
Abnormally smelly stools 8 3 2 1 NSa
Heartburn 2 1 2 1 NSa
Duration of symptoms before 
diagnosis (days, median)b 180 (IQR: 345; range: 2–3,650) 45 (IQR: 106; range: 1–1,800) <0.001
c
IQR: interquartile range; NS: not significant.
a 2-sided Fisher’s Exact test.
b Data missing for 162 patients in the Dientamoeba group and for 97 patients in the Giardia group.
c Mann–Whitney U-test.
As for asymptomatic cases: 23 asymptomatic Dientamoeba and four asymptomatic Giardia cases were found when asymptomatic family 
members of symptomatic carriers were screened for intestinal parasites. Faecal samples of 18 Dientamoeba and 12 Giardia asymptomatic 
cases were examined for unknown reasons. Six Dientamoeba and four Giardia asymptomatic cases were detected when investigating the 
subjects’ peripheral venous eosinophilia. Two asymptomatic Dientamoeba cases were found in routine examination of faeces from faecal 
material donors.
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Treatment success
We evaluated the association between faecal clear-
ance and clinical success. Our data showed a distinct 
correlation between the two (p < 0.001), consistent 
with several previous investigations [2,11,16-19]. 
However, this finding appears to contradict four 
recent paediatric studies reporting no association 
between eradication and symptom relief [20,21] or 
between Dientamoeba carriage and symptoms [33,34]. 
Indeed, scrutinising our data separately for subgroups 
of children and adults, a difference was revealed: 
parasitological clearance and clinical outcome were 
not found to be closely connected (p = 0.683) among 
children, while a significant correlation was observed 
(p < 0.001) for adults. This may simply reflect adults’ 
better skills in describing their symptoms.
The possibility that some of the treatment fail-
ures actually were reinfections cannot be ruled out. 
Transmission within families, especially in house-
holds with small children, appears common [35]. Data 
on family members were not collected, since they are 
rarely found in patient charts. Variation in failure rates 
has been shown between various regimens [36], dem-
onstrating that a substantial part of treatment failures 
are not reinfections.
Doubts about the pathogenicity of  D. fragilis  are 
presumably related to diagnostic challenges and 
high proportion of asymptomatic carriers, especially 
among children [33,34]. In studies with no correla-
tion between clinical and microbiological outcomes, 
the protozoan has been identified by PCR [20,21], the 
sensitive method enabling detection of minuscule 
amounts of microbes [37,38]. No data exist on positive 
correlation between asymptomatic individuals’ PCR 
findings and high CT  values in PCR. In fact, we found 
no studies exploring the CT values among symptomatic 
adult patients without irritable bowel syndrome (IBS); 
studies applying IBS criteria are not valid for dienta-
moebiasis, since they only cover patients with a certain 
selection of symptoms (Rome III criteria). No correla-
tion has been found between dientamoebiasis and 
IBS-type symptoms in previous investigations [39].
Limitations
The principal limitations reside in the retrospec-
tive study setting and the diagnostics: Firstly, other 
pathogens were not conclusively excluded from 
all patients. Viral enteropathogens and diarrhoea-
genic  Escherichia coli, for example, were not tested 
at HUSLAB during the study period. However, these 
pathogens typically cause acute watery diarrhoea 
[28,29], not the clinical picture characteristic of dien-
tamoebiasis that we described. Secondly, in cases 
where a trichrome sample had not been taken, the 
exclusion of dientamoebiasis in the  Giardia  group 
relied on formalin-fixed samples. This should not be a 
crucial point: presuming a specificity of 83.3% for the 
formalin-fixed sample to identify  Dientamoeba  would 
give in the  Giardia  group 23 false-negative results at 
most. With 23 false-negative  Dientamoeba  patients, 
the co-infection rate of dientamoebiasis and giardia-
sis would be 9% (34/375) (Supplementary Table S1). 
Thirdly, the symptoms could only be reported according 
to what the clinician had recorded in the patient charts; 
this limitation applies to the Dientamoeba and Giardia 
groups alike. Finally, our study design did not allow 
estimating the proportion of asymptomatic subjects in 
the  Dientamoeba  group, which can be assumed to be 
high.
Conclusions 
We present an increase in the number 
of  Dientamoeba  findings presumably stemming 
from implementation of a simple and inexpensive 
novel diagnostic approach to screen dientamoebia-
sis from formalin-fixed samples. This approach may 
prove valuable also – and especially – in low-income 
countries, where microscopy often remains the only 
diagnostic laboratory tool available. Already before 
the implementation of PCR methods, our approach 
revealed Dientamoeba to be much more common in the 
Helsinki Metropolitan Area than previously thought. 
In fact, the rate exceeds that of Giardia. As abdominal 
complaints are among the most common reasons for 
seeking medical care, active efforts are warranted to 
increase clinicians’ awareness about this pathogen as 
a cause of prolonged stomach disorders.
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